Pricing

Watch price

4 gm+0.5 gm

4.5 gm vial

৳1,080.00 per pack

Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.

All price changes →

M

Megacilin

Rx

4 gm+0.5 gm • IV Infusion

Piperacillin + Tazobactam • Popular Pharmaceuticals PLC

Therapeutic class: Broad spectrum penicillins

🌐 বাংলায় দেখুন

From ৳1,080.00 4.5 gm vial

Available as: 4 gm+0.5 gm · 4.5 gm vial 4 gm+0.5 gm 4 gm+0.5 gm 4 gm+0.5 gm

Indications & Uses

Megacilin is indicated for:

Pharmacology

Piperacillin is a broad spectrum, semi-synthetic penicillin active against many gram-positive and gram-negative aerobic and anaerobic bacteria. It works by killing bacteria through inhibition of both septum and cell wall synthesis. Tazobactam is a potent inhibitor of many beta-lactamases, including the plasmid and chromosomally mediated enzymes that commonly cause resistance to penicillins. It enhances and extends the antibiotic spectrum of Piperacillin to include many beta-lactamase-producing bacteria normally resistant to it. Thus, this infusion combines the properties of a broad-spectrum antibiotic and a beta-lactamase inhibitor.

Dosage Reference

Reference Information Only

Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.

Adults:

Piperacillin and tazobactam should be given by intravenous infusion over 30 minutes.

Adult Patients: The usual total daily dose of piperacillin and tazobactam for adults is 3.375 g every six hours, totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam) per day. Treatment is usually continued for 7 to 10 days.

Nosocomial Pneumonia: Initial presumptive treatment of patients with nosocomial pneumonia should start with piperacillin and tazobactam at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam) per day. The recommended duration of treatment for nosocomial pneumonia is 7 to 14 days. Treatment with the aminoglycoside should be continued in patients from whom Pseudomonas aeruginosa is isolated.

Pediatric Patients: For children with appendicitis and/or peritonitis who are 9 months of age or older, weigh up to 40 kg, and have normal renal function, the recommended dosage is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight, every 8 hours. For pediatric patients between 2 months and 9 months of age, the recommended dosage, based on pharmacokinetic modeling, is 80 mg piperacillin/10 mg tazobactam per kilogram of body weight, every 8 hours. Pediatric patients weighing over 40 kg with normal renal function should receive the adult dose. How to adjust the dosage in pediatric patients with renal impairment has not yet been determined.

Side Effects

Adverse events mainly affecting the skin, including rash, pruritus and purpura; the gastrointestinal system, including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions, including fever, injection site reaction (≤1%) and rigors (≤1%); immune system disorders, including hypersensitivity reactions and anaphylactic/anaphylactoid reactions, including shock (≤1%); infections such as candidiasis and pseudomembranous colitis (≤1%); metabolism and nutrition disorders such as hypoglycemia (≤1%); musculoskeletal and connective tissue disorders such as myalgia and arthralgia (≤1%); psychiatric disorders such as insomnia; and vascular disorders such as phlebitis, thrombophlebitis (≤1%), hypotension (≤1%) and flushing (≤1%). Respiratory, thoracic and mediastinal disorders may include epistaxis (≤1%).

Cautions & Contraindications

Warnings & Precautions

Serious hypersensitivity reactions (anaphylactic or anaphylactoid) have been reported in patients receiving Piperacillin and tazobactam. If such a reaction occurs, stop the medicine. Piperacillin and tazobactam may also cause severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis. If a rash keeps getting worse, stop the medicine. Hematological effects have occurred, including bleeding, leukopenia and neutropenia. During prolonged therapy, monitor hematologic tests. Nephrotoxicity has been observed in critically ill patients. In a randomized, multicenter, controlled trial in critically ill patients, Piperacillin and tazobactam was found to be an independent risk factor for renal failure. It was also linked to slower recovery of renal function than other beta-lactam antibacterial drugs. Because of this, alternative treatment options should be considered in the critically ill population. If those alternatives are inadequate or unavailable, monitor renal function during treatment with Piperacillin and tazobactam. Clostridium difficile associated diarrhea: if a patient develops diarrhea, evaluate them.

Contraindications

Piperacillin + tazobactam should not be used in patients who have previously had an allergic reaction to any penicillin, cephalosporin, or β-lactamase inhibitor.

Pregnancy & Breastfeeding

Piperacillin and tazobactam are both known to cross the placenta in humans. That said, there isn't enough data on their use during pregnancy to determine whether they carry any risk of major birth defects or miscarriage. Piperacillin does pass into human breast milk, while tazobactam's presence in breast milk hasn't been studied. Whether the combination affects a breastfeeding baby or a mother's milk supply is also not currently known.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Use in Special Populations

Pediatric Use: Piperacillin and tazobactam can be used in children aged 2 months or older who have appendicitis and/or peritonitis. This is backed by well-controlled studies, and by pharmacokinetic studies in adults and in children. How to adjust the dose of Piperacillin and tazobactam in children with renal impairment has not been determined.

Geriatric Use: Patients over 65 years are not at an increased risk of adverse effects just because of their age. The dose should still be adjusted if there is renal impairment, and this may be clinically important in diseases such as congestive heart failure.

Renal Impairment: If creatinine clearance is ≤40 mL/min, or the patient is on dialysis (hemodialysis and CAPD), the intravenous dose of Piperacillin and tazobactam should be reduced according to the degree of renal function impairment.

Hepatic Impairment: No dose adjustment of Piperacillin and tazobactam is needed in patients with hepatic cirrhosis.

Patients with Cystic Fibrosis: As with other semisynthetic penicillins, piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.

Overdose

Overdose of piperacillin/tazobactam has been reported after the medicine came into general use. Most of the effects seen, such as nausea, vomiting and diarrhea, are also reported at the usual recommended doses. If higher than recommended doses are given intravenously, patients may develop neuromuscular excitability or convulsions, particularly when kidney function is poor (renal failure). Treatment is supportive and symptomatic, based on how the patient presents clinically.

⚠️ In an emergency call 999 or go to the nearest hospital emergency department.

Storage

Store Piperacillin + Tazobactam below 30°C, away from light and moisture. Keep it out of the reach of children.

Drug Interactions

Open checker →

Moderate Methotrexate

Moderate Tobramycin

Moderate Vecuronium Bromide

Moderate Heparin Sodium

Common questions about Megacilin 4 gm+0.5 gm

What is Megacilin 4 gm+0.5 gm IV Infusion?

Megacilin 4 gm+0.5 gm IV Infusion is a medicine that contains Piperacillin + Tazobactam. It is made by Popular Pharmaceuticals PLC. It belongs to the Broad spectrum penicillins group of medicines.

What is Megacilin used for?

Megacilin is used for: Pneumonia, Skin and Soft Tissue Infection.

What are the side effects of Megacilin?

Adverse events mainly affecting the skin, including rash, pruritus and purpura; the gastrointestinal system, including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions, including fever, injection site reaction (≤1%) and rigors (≤1%); immune system disorders, including hypersensitivity reactions and anaphylactic/anaphylactoid reactions, including shock (≤1%); infections such as candidiasis and pseudomembranous colitis (≤1%); metabolism and nutrition disorders such as hypoglycemia (≤1%); musculoskeletal and connective tissue disorders such as myalgia and arthralgia (≤1%); psychiatric disorders such as insomnia; and vascular disorders such as phlebitis, thrombophlebitis (≤1%), hypotension (≤1%) and flushing (≤1%). Respiratory, thoracic and mediastinal disorders may include epistaxis (≤1%).

Can I take Megacilin during pregnancy or while breastfeeding?

Piperacillin and tazobactam are both known to cross the placenta in humans. That said, there isn't enough data on their use during pregnancy to determine whether they carry any risk of major birth defects or miscarriage. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

What happens if I take too much Megacilin?

Overdose of piperacillin/tazobactam has been reported after the medicine came into general use. Most of the effects seen, such as nausea, vomiting and diarrhea, are also reported at the usual recommended doses. In an emergency call 999 or go to the nearest hospital emergency department.

How should I store Megacilin?